How a CRISPR sickle cell therapy moved from lab to clinical trial

A UCLA-led team advanced a CRISPR-Cas9 sickle cell therapy from lab concept to clinical-trial-ready manufacturing. The approach directly corrects the disease-causing mutation in a patient’s own blood-forming stem cells and showed promising preclinical safety, durability, and hemoglobin improvements.